Skip to main content
. 2011 Jul 29;3:16. doi: 10.1186/2045-824X-3-16

Table 4.

Best response according to RECIST and treatment duration

Parameter Non-continuous dosing (n = 11) Continuous dosing (n = 28) Total (n = 39)
Status at study entry (SD/PD) 1 (9%)/10 (91%) 0 (0%)/28 (100%) 1 (3%)/38 (97%)
Best response
- Stable disease 6 (55%) 16 (57%) 22 (56%)
- Progressive disease measurement proven 4 (36%) 9 (32%) 13 (33%)
- Progressive disease by clinical judgment 1 (9%) 3 (11%) 4 (10%)

- PD - progressive disease

- SD - stable disease.